The news of JP Morgan maintaining an Overweight rating and raising the price target for Intra-Cellular Therapies is positive for the stock. This indicates that the analyst believes the stock will outperform the market, and the increased price target suggests a higher potential upside. This is likely to have a positive short-term impact on the stock price.